217 related articles for article (PubMed ID: 33464636)
1. COVID-19 vaccines: the importance of transparency and fact-based education.
Cohen AF; van Gerven J; Burgos JG; de Boer A; Foucher RAM; Flore H; Teitelbaum Z; van Eden W; Webb A; Cremers S
Br J Clin Pharmacol; 2020 Nov; 86(11):2107-2110. PubMed ID: 33464636
[No Abstract] [Full Text] [Related]
2. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
He Q; Mao Q; Zhang J; Bian L; Gao F; Wang J; Xu M; Liang Z
Front Immunol; 2021; 12():669339. PubMed ID: 33912196
[TBL] [Abstract][Full Text] [Related]
3. Communicating COVID-19 vaccines: lessons from the dengue vaccine controversy in the Philippines.
Lasco G; Yu VG
BMJ Glob Health; 2021 Mar; 6(3):. PubMed ID: 33653732
[No Abstract] [Full Text] [Related]
4. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
5. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
[TBL] [Abstract][Full Text] [Related]
6. Covid-19: Use social media to maximise vaccine confidence and uptake.
Patten D; Green A; Bown D; Russell C
BMJ; 2021 Jan; 372():n225. PubMed ID: 33500243
[No Abstract] [Full Text] [Related]
7. Severe mental illness: reassessing COVID-19 vaccine priorities.
Siva N
Lancet; 2021 Feb; 397(10275):657. PubMed ID: 33610199
[No Abstract] [Full Text] [Related]
8. COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
Karafillakis E; Van Damme P; Hendrickx G; Larson HJ
Lancet; 2022 Feb; 399(10326):699-701. PubMed ID: 35123665
[No Abstract] [Full Text] [Related]
9. Key populations for early COVID-19 immunization: preliminary guidance for policy.
Ismail SJ; Zhao L; Tunis MC; Deeks SL; Quach C;
CMAJ; 2020 Nov; 192(48):E1620-E1632. PubMed ID: 33144317
[No Abstract] [Full Text] [Related]
10. COVID-19 vaccines approved in the European Union: current evidence and perspectives.
Bellino S
Expert Rev Vaccines; 2021 Oct; 20(10):1195-1199. PubMed ID: 34338126
[No Abstract] [Full Text] [Related]
11. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
12. Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.
Baay M; Neels P
Front Immunol; 2021; 12():658783. PubMed ID: 33777056
[No Abstract] [Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
14. India's COVID-19 vaccination drive: key challenges and resolutions.
Choudhary OP; Choudhary P; Singh I
Lancet Infect Dis; 2021 Nov; 21(11):1483-1484. PubMed ID: 34529961
[No Abstract] [Full Text] [Related]
15. Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?
Van Dreden P; Fareed J; Elalamy I; Gerotziafas G
Clin Appl Thromb Hemost; 2021; 27():10760296211033906. PubMed ID: 34689575
[No Abstract] [Full Text] [Related]
16. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
17. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
18. COVID-19: vaccination problems.
Brüssow H
Environ Microbiol; 2021 Jun; 23(6):2878-2890. PubMed ID: 33928745
[TBL] [Abstract][Full Text] [Related]
19. Transforming COVID-19 vaccines into vaccination : Challenges and opportunities for management scientists.
Dai T; Song JS
Health Care Manag Sci; 2021 Sep; 24(3):455-459. PubMed ID: 34132977
[TBL] [Abstract][Full Text] [Related]
20. Considerations in boosting COVID-19 vaccine immune responses.
Krause PR; Fleming TR; Peto R; Longini IM; Figueroa JP; Sterne JAC; Cravioto A; Rees H; Higgins JPT; Boutron I; Pan H; Gruber MF; Arora N; Kazi F; Gaspar R; Swaminathan S; Ryan MJ; Henao-Restrepo AM
Lancet; 2021 Oct; 398(10308):1377-1380. PubMed ID: 34534516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
